Rationale and design of a randomized clinical trial of beta-blocker therapy (atenolol) versus angiotensin II receptor blocker therapy (losartan) in individuals with Marfan syndrome - sprookjes - yvandenbroek - TriplyDB

Rationale and design of a randomized clinical trial of beta-blocker therapy (atenolol) versus angiotensin II receptor blocker therapy (losartan) in individuals with Marfan syndrome

Rationale and design of a randomized clinical trial of beta-blocker therapy (atenolol) versus angiotensin II receptor blocker therapy (losartan) in individuals with Marfan syndrome

http://www.wikidata.org/entity/Q30476899

about

Beta-blockers for preventing aortic dissection in Marfan's syndrome Medical treatment of aortic aneurysms in Marfan syndrome and other heritable conditions Epidemiology and pathophysiology of mitral valve prolapse: new insights into disease progression, genetics, and molecular basis Educational paper. Connective tissue disorders with vascular involvement: from gene to therapy Angiotensin II blockade and aortic-root dilation in Marfan's syndrome Identification of therapeutic candidates for chronic lymphocytic leukemia from a library of approved drugs Comparative measurement of aortic root by transthoracic echocardiography in normal Korean population based on two different guidelines High prevalence of eosinophilic esophagitis in patients with inherited connective tissue disorders.BMP signaling modulation attenuates cerebral arteriovenous malformation formation in a vertebrate model Rapid cell culture and pre-clinical screening of a transforming growth factor-beta (TGF-beta) inhibitor for orthopaedics.Angiotensin II infusion promotes ascending aortic aneurysms: attenuation by CCR2 deficiency in apoE-/- mice.The role of the renin-angiotensin system in aortic aneurysmal diseases.The economic impact of Marfan syndrome: a non-experimental, retrospective, population-based matched cohort study.Report of the National Heart, Lung, and Blood Institute and National Marfan Foundation Working Group on research in Marfan syndrome and related disorders.Characteristics of children and young adults with Marfan syndrome and aortic root dilation in a randomized trial comparing atenolol and losartan therapy Drug-based therapies for vascular disease in Marfan syndrome: from mouse models to human patients.A prospective, randomized, placebo-controlled, double-blind, multicenter study of the effects of irbesartan on aortic dilatation in Marfan syndrome (AIMS trial): study protocol.Lessons learned from a pediatric clinical trial: the Pediatric Heart Network angiotensin-converting enzyme inhibition in mitral regurgitation study Endothelial cell-specific deficiency of Ang II type 1a receptors attenuates Ang II-induced ascending aortic aneurysms in LDL receptor-/- mice.The NCGC pharmaceutical collection: a comprehensive resource of clinically approved drugs enabling repurposing and chemical genomics Preventing the aortic complications of Marfan syndrome: a case-example of translational genomic medicine Atenolol versus losartan in children and young adults with Marfan's syndrome.Design and rationale of a prospective, collaborative meta-analysis of all randomized controlled trials of angiotensin receptor antagonists in Marfan syndrome, based on individual patient data: A report from the Marfan Treatment Trialists' Collaborat Genetics for the general internist Transforming growth factor beta signaling in adult cardiovascular diseases and repair.Novel pharmacological strategies to prevent aortic complications in Marfan syndrome.Matrix-dependent perturbation of TGFβ signaling and disease Bicuspid aortic valve and thoracic aortic aneurysm: three patient populations, two disease phenotypes, and one shared genotype.Impact of Mendelian inheritance in cardiovascular disease.Fibrillin-containing microfibrils are key signal relay stations for cell function.Postnatal Deletion of the Type II Transforming Growth Factor-β Receptor in Smooth Muscle Cells Causes Severe Aortopathy in Mice Lessons on the pathogenesis of aneurysm from heritable conditions The pathology and pathobiology of bicuspid aortic valve: State of the art and novel research perspectives.Adults with genetic syndromes and cardiovascular abnormalities: clinical history and management.Echocardiographic methods, quality review, and measurement accuracy in a randomized multicenter clinical trial of Marfan syndrome.Hereditary Influence in Thoracic Aortic Aneurysm and Dissection.Long-term effects of losartan on structure and function of the thoracic aorta in a mouse model of Marfan syndrome.Abnormal muscle mechanosignaling triggers cardiomyopathy in mice with Marfan syndrome.The pathogenesis of aortopathy in Marfan syndrome and related diseases.The pediatric heart network: meeting the challenges to multicenter studies in pediatric heart disease.

P2860

Q24194883-7C705DAE-4534-41EC-A42C-D9F774610A9D Q26823672-2A83A2EA-9A14-4864-BBC4-AE05D7DF66FD Q26828458-F8772696-5394-428A-AC65-24EBCF950070 Q26853455-8858E7C2-31BD-4E2F-BE81-F5E6C557579D Q28285199-ED936F69-AAF7-4E1A-8AC7-FB1640C2884A Q28533669-D244B60F-5EE7-4476-B73E-206D173839A1 Q30450362-095C679A-98A1-4DAB-9252-F1EC4FBB2D6E Q30554334-F7DCEA35-70C0-475A-BA2E-43FB3B879E54 Q30609102-630CA35A-BA3C-4A58-BD12-2826AB831C9C Q30983801-A1319888-EC91-4AC5-B0FA-C71BB34C1E87 Q33738515-36972AAC-CAB2-455E-BA49-F5915B47FDDC Q33757332-20E1E91B-56A7-4175-A01F-043E74A4E99E Q33848798-648E3AEA-EF07-4546-AF0B-3E466DC9A69A Q34017755-77CFDAC7-2D53-4E0C-847D-A8A844E9A799 Q34039474-713C4724-FF6B-4B64-B258-DEEC6103AE08 Q34051477-B0D43B46-0495-4724-858A-D7532C85D319 Q34455509-421BC651-D724-44FA-AD88-183E5CCC0007 Q34645459-60AB97B3-7EB6-4497-8073-45191D835D57 Q34790053-FC3C0148-5454-4997-9B96-5E03BD05A3BC Q34992596-48D9CFC1-5342-42FC-B9DD-B30A14909EFA Q35120570-3AAEB6DF-938B-41AF-A102-540077D6603C Q35282583-79B3F39E-B68A-476E-98CD-383F4B5C1CBC Q35628022-E5534AE4-709F-4672-9DF6-9131F6065F78 Q35634020-E2212B69-05E8-4037-9F45-AFE8FD747D4C Q35895390-3CBE584C-A52F-420D-9B9D-086F4AF707A8 Q36077356-B5E95BDB-2825-4DE4-84DC-82C0534E5FE2 Q36184322-5CD05605-3BB0-49E7-AD2A-CDACC0CB5E7D Q36210512-54A2B382-989A-4DB9-944B-794165F3728C Q36371337-F06FFF14-8CF5-4368-843C-4A08EF6F1659 Q36470965-B35214CB-ABA9-4353-BD6E-40709BFC344A Q36551449-2D293CD6-B617-4B6B-BAD2-DD0FB66C7237 Q36756427-9487E0ED-CDC8-4E07-A2C0-9FDAF7FB2E52 Q37082556-EA08126E-444A-4D67-A8B2-CD9F075741BF Q37164120-C6C08FDA-54BF-404E-89A9-7148C3B3F481 Q37187764-1D4DBC8E-1737-4781-AF48-0FC9618BE60F Q37272866-BD5953C5-5092-44D3-9702-B441D2179800 Q37481205-6E11E69F-6308-4B04-831F-AB1376643607 Q37602214-3750CFCD-A6A0-41F3-AC8F-1AF03F9B3581 Q37738226-7F86B26F-4780-4BFB-B5AB-3BD9B6915F8C Q37739602-004BCE2B-C489-4C41-AD70-3F436FA89CC7

P2860

Rationale and design of a randomized clinical trial of beta-blocker therapy (atenolol) versus angiotensin II receptor blocker therapy (losartan) in individuals with Marfan syndrome

http://www.wikidata.org/entity/Q30476899

description

2007 nî lūn-bûn

@nan

2007 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2007 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

name

Rationale and design of a rand ...... dividuals with Marfan syndrome

@ast

Rationale and design of a rand ...... dividuals with Marfan syndrome

@en

type

label

Rationale and design of a rand ...... dividuals with Marfan syndrome

@ast

Rationale and design of a rand ...... dividuals with Marfan syndrome

@en

prefLabel

Rationale and design of a rand ...... dividuals with Marfan syndrome

@ast

Rationale and design of a rand ...... dividuals with Marfan syndrome

@en

P1433

Q30476899-A62334D2-6B07-403C-B55A-AA4421BFCFA8

P1476

Q30476899-3297F664-4F05-43C1-BCA2-9D714C4FCE3C

P2093

Q30476899-0E965048-E13A-4771-9E45-F4BEF34F34AC

Q30476899-16C820E2-EB75-4AE0-BAEA-501417BCA24C

Q30476899-280E1FE8-E2B3-4973-A25B-6B63FA23D81F

Q30476899-28C1E878-42C1-4CCB-A57C-188BCC3932F1

Q30476899-3091DEF8-3A58-4ED8-BC08-6BAC1A978623

Q30476899-35C198EF-5F4C-4FEA-AFC6-E6A7B69A8A89

Q30476899-3E72E01D-81CB-48F4-B7C9-6AEA481E1852

Q30476899-3FCA41AA-E427-4D18-8285-A159BA60CF37

Q30476899-4954B61A-0AC8-44E7-858D-1AF73691733E

Q30476899-62E9460F-3CFF-4433-B9E7-EC0D0839A82A

P2860

Q30476899-09ADD74A-2624-479E-B113-16E02B16CC1D

Q30476899-175849B3-D0C5-4CE6-B1D2-865A370088DB

Q30476899-1867419C-BECC-4137-A069-A7169D5E9781

Q30476899-1D6038E6-B2D8-414E-8FF6-41C9E7BFB41D

Q30476899-2AB181D7-6475-45C3-98BD-5F836CAB2559

Q30476899-3E58E227-6988-47AE-B96D-5E25CBCD53B9

Q30476899-408A8414-29CF-47B0-B94C-0003F0758281

Q30476899-47E57C4E-8B7F-4594-97F5-A004243B6C7D

Q30476899-48D6A008-B8A2-4382-B609-A28FC2151133

Q30476899-4F258EFC-9E3E-4ADA-89FF-4AFBE9F731A2

P304

Q30476899-FEEE9A0A-75EE-43A7-9CF5-DD1C6CD5CE0E

P31

Q30476899-1AC1A341-4E6A-4756-8C1E-BB7F3EF1F38F

Q30476899-FE723EC8-516D-40A2-9C13-13B5B2EF4A0E

P356

Q30476899-A185C5EB-F1BB-41D2-8765-1D0956C04C3D

P407

Q30476899-6E0DB53A-7934-48C2-987C-D5F565AA8750

P433

Q30476899-CE26D096-8813-4CC4-84AF-7B37CE3EABFF

P478

Q30476899-17806122-BD13-4CBF-805C-49263452DCED

P50

Q30476899-4C4434D1-7C30-4F2C-8912-5CB26C3A33EF

Q30476899-89D9A191-5D45-431F-8478-807BBDD3DFA5

P577

Q30476899-38C8B74D-421E-43E4-BEB4-15FFB684F386

P5875

Q30476899-2C77BA59-C5AA-44FF-89A6-71573C4DCAF2

P698

Q30476899-29C2FF72-A548-4224-BC3D-400B5C6BE22A

P932

Q30476899-1D4D3564-8113-418D-AA7E-93367F34104A

P356

J.AHJ.2007.06.024

P1433

American Heart Journal

P1476

Rationale and design of a rand ...... dividuals with Marfan syndrome

@en

P2093

Beth F Printz

http://www.w3.org/2001/XMLSchema#string

Elizabeth Radojewski

http://www.w3.org/2001/XMLSchema#string

Gail D Pearson

http://www.w3.org/2001/XMLSchema#string

Gloria L Klein

http://www.w3.org/2001/XMLSchema#string

Harry C Dietz

http://www.w3.org/2001/XMLSchema#string

J Philip Saul

http://www.w3.org/2001/XMLSchema#string

Jennifer S Li

http://www.w3.org/2001/XMLSchema#string

L LuAnn Minich

http://www.w3.org/2001/XMLSchema#string

Lisa M Wruck

http://www.w3.org/2001/XMLSchema#string

Lynn Mahony

http://www.w3.org/2001/XMLSchema#string

P2860

Purification and partial characterization of fibrillin, a cysteine-rich structural component of connective tissue microfibrils

Latent transforming growth factor beta-binding protein 1 interacts with fibrillin and is a microfibril-associated protein

Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome

Marfan's syndrome

Role of the latent transforming growth factor beta binding protein 1 in fibrillin-containing microfibrils in bone cells in vitro and in vivo

A syndrome of altered cardiovascular, craniofacial, neurocognitive and skeletal development caused by mutations in TGFBR1 or TGFBR2

Latent transforming growth factor-beta: structural features and mechanisms of activation

A multiple testing procedure for clinical trials

Dysregulation of TGF-beta activation contributes to pathogenesis in Marfan syndrome

Regulation and regulatory activities of transforming growth factor beta.

P304

624-631

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.AHJ.2007.06.024

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

154

http://www.w3.org/2001/XMLSchema#string

P50

Pediatric Heart Network Investigators

Richard B Devereux

P577

2007-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

246222263

http://www.w3.org/2001/XMLSchema#string

P698

17892982

http://www.w3.org/2001/XMLSchema#string

P932

3042860

http://www.w3.org/2001/XMLSchema#string